Health Care • Medical/Dental Instruments
$0.54 ▼ -0.03
(-5.08%)
MKT CAP: $2.4M • VOL: 98.3K
52W L $0 52W H $8
ROARABLE / RQD
D • 45/100
PIOTROSKI
3 / 9
BJDX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$7.0M | -$7.2M | -$10.3M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$6.8M | -$7.7M | -$10.0M |
| EBITDA (Normalized) | -$6.8M | -$6.9M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$6.1M | -$7.8M | -$8.3M |
| Capital Expenditures (CapEx) | $173.7K | $306.8K | — |
| Free Cash Flow (FCF) | -$6.2M | -$8.1M | -$8.3M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $5.2M | $4.3M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $6.0M | $5.7M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR BJDX.